title: Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
abstract: Screening by ofloxacin disk was carried out on 1158 strains of Streptococcus pneumoniae in order to investigate the in vitro bacteriostatic activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, linezolid, pristinamycin and quinupristin-dalfopristin against ofloxacin-intermediate and -resistant S. pneumoniae strains. It was concluded that these new antimicrobial agents could be useful for the treatment of pneumococcal infections caused by penicillin-sensitive and -resistant S. pneumoniae, and would represent a valid therapeutic option for patients allergic to beta-lactams, should they prove to be potent in vivo.
authors.affiliation: Laboratoire de Microbiologie, Centre Hospitalier Lyon-Sud, 165 chemin du Grand Revoyet, 69310 Pierre-Bénite, France.
authors.forename: I
authors.initials: I
authors.lastname: Frédénucci
authors.forename: M
authors.initials: M
authors.lastname: Chomarat
authors.forename: R
authors.initials: R
authors.lastname: Bercion
authors.forename: A
authors.initials: A
authors.lastname: Carricajo
authors.forename: M
authors.initials: M
authors.lastname: Celard
authors.forename: J
authors.initials: J
authors.lastname: Croizé
authors.forename: F
authors.initials: F
authors.lastname: Delubac
authors.forename: D
authors.initials: D
authors.lastname: Fèvre
authors.forename: C
authors.initials: C
authors.lastname: Fuhrmann
authors.forename: M
authors.initials: M
authors.lastname: Helfre
authors.forename: M N
authors.initials: MN
authors.lastname: Letouzey
authors.forename: H
authors.initials: H
authors.lastname: Lelièvre
authors.forename: A
authors.initials: A
authors.lastname: Mandjee
authors.forename: P
authors.initials: P
authors.lastname: Marthelet
authors.forename: R
authors.initials: R
authors.lastname: Meley
authors.forename: J D
authors.initials: JD
authors.lastname: Perrier-Gros-Claude
authors.forename: A
authors.initials: A
authors.lastname: Ros
authors.forename: C
authors.initials: C
authors.lastname: Roure
authors.forename: S
authors.initials: S
authors.lastname: Smati
authors.forename: J
authors.initials: J
authors.lastname: Thierry
authors.forename: J
authors.initials: J
authors.lastname: Tous
mesh_terms: D000081:Acetamides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology; D001372:Aza Compounds; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones; D048628:Ketolides; D007769:Lactams / Q000276:immunology; D064704:Levofloxacin; D000069349:Linezolid; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000276:immunology / Q000494:pharmacology*; D023303:Oxazolidinones / Q000494:pharmacology; D010400:Penicillin G / Q000494:pharmacology; D025762:Pristinamycin / Q000494:pharmacology; D011804:Quinolines; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000472:pathogenicity; D014769:Virginiamycin / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D048628:Ketolides; D007769:Lactams; D018942:Macrolides; D023303:Oxazolidinones; D025762:Pristinamycin; D011804:Quinolines; D014769:Virginiamycin; C113825:quinupristin; D064704:Levofloxacin; D015242:Ofloxacin; D000069349:Linezolid; C106791:telithromycin; D010400:Penicillin G; C113826:dalfopristin; D000077266:Moxifloxacin